Press release
PARP Inhibitors Drug Therapy Market worth $12.43 billion by 2030, growing at a CAGR of 9.15% - Exclusive Report by 360iResearch
PARP Inhibitors Drug Therapy Market | 360iResearch
Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/parp-inhibitors-drug-therapy?utm_source=openpr&utm_medium=referral&utm_campaign=sample
The PARP (Poly ADP-Ribose Polymerase) inhibitors drug therapy market focuses on drugs inhibiting the PARP enzyme, crucial in treating cancers including ovarian, breast, prostate, and pancreatic. These inhibitors, vital in DNA repair, promote cancer cell death and address unmet medical needs due to high cancer mortality rates. PARP inhibitors provide targeted therapy and align with personalized medicine trends, particularly benefiting patients with BRCA mutations. Applications span from primary cancer treatment, combination therapies, monotherapy for genetic predispositions, to maintenance therapy post-chemotherapy. Major end-users include hospitals, cancer treatment centers, pharmaceutical companies, and academic and research institutes. Market growth is driven by increasing cancer incidence, advancements in genetic screening, regulatory approvals, and ongoing R&D investments. Key opportunities include expanding indications beyond BRCA-mutant cancers, geographic expansion into developing countries, forming partnerships for enhanced R&D, and developing oral PARP inhibitors for better patient compliance. Recommendations emphasize investing in next-gen PARP inhibitors, developing robust regulatory strategies, educating healthcare professionals, and enhancing patient access through support programs. However, the market faces challenges such as the high cost of treatment, drug resistance, side effects, regulatory hurdles, and strong competition from alternative therapies. Areas for innovation include research into synthetic lethality, next-gen PARP inhibitors with improved efficacy and safety, innovative combination regimens, biomarker development to predict responses, and advanced drug delivery systems. The rapidly evolving market is characterized by substantial R&D investments and technological advancements, with a focus on improving cancer treatment outcomes, extending patient survival, and enhancing patient quality of life, heavily influenced by regulatory environments and collaborations between biotech and pharmaceutical companies.
Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/parp-inhibitors-drug-therapy?utm_source=openpr&utm_medium=referral&utm_campaign=inquire
Market Segmentation & Coverage:
This research report categorizes the PARP Inhibitors Drug Therapy Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Drug, market is studied across Niraparib, Olaparib, Rucaparib, and Talazoparib.
Based on Indication, market is studied across Breast Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Key Company Profiles:
The report delves into recent significant developments in the PARP Inhibitors Drug Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Artios Pharma Limited, AstraZeneca PLC, BeiGene, Inc., Bristol-Myers Squibb Company, Clovis Oncology, GlaxoSmithKline PLC, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Company Ltd., Johnson & Johnson Services, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Repare Therapeutics, Inc..
Introducing 360iResearch AI: Revolutionizing Market Intelligence with AI-Powered Insights for the PARP Inhibitors Drug Therapy Market
We proudly unveil Research AI, a cutting-edge AI product designed to transform how businesses interact with the PARP Inhibitors Drug Therapy Market. Research AI stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, Research AI is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it's a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive PARP Inhibitors Drug Therapy Market. Embrace the future of market analysis with Research AI, where informed decisions lead to remarkable growth.
Ask Question to Research AI @ https://www.360iresearch.com/library/intelligence/parp-inhibitors-drug-therapy?utm_source=openpr&utm_medium=referral&utm_campaign=research-ai
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. PARP Inhibitors Drug Therapy Market, by Drug
7. PARP Inhibitors Drug Therapy Market, by Indication
8. PARP Inhibitors Drug Therapy Market, by Distribution Channel
9. Americas PARP Inhibitors Drug Therapy Market
10. Asia-Pacific PARP Inhibitors Drug Therapy Market
11. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market
12. Competitive Landscape
13. Competitive Portfolio
Read More @ https://www.360iresearch.com/library/intelligence/parp-inhibitors-drug-therapy?utm_source=openpr&utm_medium=referral&utm_campaign=analyst
Contact 360iResearch
Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550
About 360iResearch
360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PARP Inhibitors Drug Therapy Market worth $12.43 billion by 2030, growing at a CAGR of 9.15% - Exclusive Report by 360iResearch here
News-ID: 3588409 • Views: …
More Releases from 360iResearch
Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Globa …
In recent years, the silent ascent of human metapneumovirus (HMPV) infections has begun to capture significant attention within the realm of infectious diseases. As we advance in medical science, unraveling complexities of age-old pathogens like common influenza or emerging illnesses like COVID-19, a critical discourse has been emerging around HMPV. Particularly, there seems to be a burgeoning acknowledgment of its growing impact on vulnerable global populations, propelling an increased demand…
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and …
From Appetite to Advocacy: The Rising Demand for Meat Alternatives
In recent years, the global food industry has been undergoing a remarkable transformation, driven primarily by an increasing consumer demand for healthier, sustainable, and ethically sourced food products. This seismic shift has brought traditional meat alternatives and high-protein plant-based foods into the spotlight. As the world becomes more conscious of the implications of meat consumption on health and the environment, the…
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 202 …
Unpacking the Surge in Investments and Collaborations to Bolster Mobility-as-a-Service
In recent years, as urban landscapes continually evolve, a transformative shift known as Mobility-as-a-Service (MaaS) has reshaped the way we perceive transportation. Marked by the integration of various forms of transport services into a single accessible on-demand mobility solution, MaaS is rapidly gaining traction across global cities. As an emerging paradigm, it's not just shaping the future of travel but also…
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 …
Smart City Revolutions: Why Data Center Colocation is the Future Backbone
In the era of digital transformation, urban landscapes across the globe are undergoing a seismic shift toward becoming "smart cities." The concept of a smart city revolves around using digital technology, IoT (Internet of Things), AI, and data analytics at an unprecedented scale to improve urban infrastructure, manage resources efficiently, and enhance the quality of life for citizens. A vital…
More Releases for PARP
PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8…
Parp Inhibitors Market Driven by Demand for Immersive Technologies Across Indust …
Global Parp Inhibitors Market Impact of AI and Automation
The PARP inhibitors market has seen remarkable growth in recent years, primarily driven by advances in cancer treatment and the increasing prevalence of cancer globally. These inhibitors, which block the enzyme poly (ADP-ribose) polymerase (PARP), are proving to be highly effective in targeting specific cancer cells, especially in cancers with DNA repair deficiencies like ovarian, breast, and prostate cancers. The approval of…
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
